Gufic BioScience

Gufic Biosciences reported a Q3 FY26 turnover of INR 231.1 crores, a marginal increase from INR 230.4 crores in Q2 FY26. EBITDA saw a slight decline to INR 37.1 crores from INR 37.9 crores QoQ, resulting in margin compression to 16.05%. Profit After Tax, however, improved by 4.7% QoQ to INR 15.6 crores. The company consciously took a hit of INR 14-16 crores in Q3, and expects INR 3-5 crores in Q4, as part of a strategic revamp to control debtors and shift from direct hospital billing to a stockist model for Sparsh and Critical Care segments, which had previously affected working capital.

The Indore plant's ramp-up is progressing in a step-wise, compliance-first manner. Output from Indore has increased from an average of INR 25-26 crores to INR 38-42 crores, with a target to reach INR 40-42 crores. The EU audit for the Indore facility was completed in December 2025, and the certificate is expected by March or April 2026. This approval is crucial for enabling an uplift in EU market revenues from Indore, anticipated by Q2 or Q3 FY27.

The international business, particularly formulations exports, is showing strong growth, increasing by approximately INR 60-70 crores from a base of INR 120 crores. The Botulinum Toxin segment, branded Stunnox, has achieved a 23% market share in India, with revenues of INR 25-30 crores, and is growing at 20-25%. The company is also building capability for a broader aesthetic platform, including the upcoming launch of a fillers product by June-July 2026 through an agreement with a Canadian company, which is expected to further boost market share.

Within the domestic branded portfolio, the focus remains on protocol-led depth and science-backed differentiation. Critical Care is concentrating on sepsis and resistant infections, while Sparsh is building differentiation through formats like dual chamber bags and plans to launch contrast media and total parenteral nutrition. The Women's Health platform, with brands like Guficin Alpha and Puregraf, continues to compound well, with the Ferticare segment growing 16-17%. The pipeline for women's health includes therapy tools for endometriosis, PCOS, and menopause.

Management targets a minimum of 15% revenue growth for FY27. In the long term, as Indore's capacity utilization rises above 50% (expected after 2-3 years), EBITDA margins are projected to improve from the current 16% to 19%. If utilization reaches over 75%, margins could further expand to 20-21%. The company aims to maintain its current debt level of INR 375 crores until March 2027 and reduce average receivable days from 140 to 120 in FY26.

Gufic is progressing with advanced molecules like Thymosin Alpha-1 (Immunocin-Alpha), Dalbavancin (Dalbavan), and Isavuconazole (Isavufic) for critical care. The company is also building a high lifetime value franchise in the Toxin Platform through injector creation and clinical data generation. The Nutra and Ayurveda platform is sharpening its focus on chronic care, with products like upgraded Gufican Oil and Vonoprazan (Vonpha). The long-term cancer vaccine project, Selvax, is still 5-6 years away from commercialization.